Zafiride: Withdrawal of the marketing authorisation application

ngr-human tumour necrosis factor alpha

Overview

On 1 June 2017, MolMed S.p.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Zafiride for the treatment of advanced malignant pleural mesothelioma.

  • List item

    Questions and answers on the withdrawal of the marketing authorisation application for Zafiride (NGR-human tumour necrosis factor alpha) (PDF/74.17 KB)


    First published: 23/06/2017
    Last updated: 23/06/2017
    EMA/393395/2017

  • Key facts

    Name
    Zafiride
    Product number
    EMEA/H/C/004455
    International non-proprietary name (INN) or common name
    • ngr-human tumour necrosis factor alpha
    Active substance
    • ngr-human tumour necrosis factor alpha
    Date of withdrawal
    01/06/2017
    Company making the application
    MolMed SpA
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter (withdrawal letter Doc. type, leave the 'Author' in properties blank).

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating